Yes there are competitors of course, but consider the value that Viaderma has IN HAND right now. To give you an idea, take a look at this, a similar type of technology but which uses an electrical device, unlike Viaderma which has a physical mechanism of action in the liquid itself:
TransPharma based in Lod, Israel, had generated some promising buzz with its ViaDor technology, and explored its use in areas other than dermatology and cosmetic indications. The company inked a development/licensing deal with Eli Lilly ($LLY) in 2008, worth at least $35 million upfront, involving a version of Lilly's osteoporosis drug Forteo that incorporated TransPharma's delivery system technology, the business innovation news wire Israel21c reported at the time. In 2010, TransPharma successfully completed a Phase Ia trial using its then-named ViaDerm-GlP1 agonist to treat Type 2 diabetes, among other milestones. --http://www.fiercedrugdelivery.com/drug-delivery/syneron-grabs-transpharma-assets-gains-novel-transdermal-drug-delivery-tech
News 
Market Data 
Discover 
